Buruli ulcer

Professor Jacques Grosset

Nationality: French

E-mail: jgrosse4@jhmi.edu

Present position

  • Visiting Professor of Medicine, Johns Hopkins University School of Medicine

Areas of expertise/interest

  • Experimental chemotherapy
  • Clinical trials

Recent publications

  • Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, Evans M, Ofori-Adjei D, Klustse E, Owusu-Boateng J, Amedofu GK, Awuah P, Ampadu E, Amofah G, Asiedu K, Wansbrough-Jones M. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother. 2005 Aug;49(8):3182-6. [Abstract]
  • Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother. 2002 Oct;46(10):3193-6. [Abstract/Free full text]
  • Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, Grosset J. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother. 2001 Nov;45(11):3109-12. [Abstract/Free full text]
  • Dega H, Chosidow O, Barete S, Carbonnelle B, Grosset J, Jarlier V. Mycobacterium ulcerans infection. Ann Med Interne (Paris). 2000 Sep;151(5):339-44. [Abstract]
  • Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother. 2000 Sep;44(9):2367-72. [Abstract/Free full text]
  • Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, Johnson C, Aubry J, Nuermberger E, Grosset J. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother. 2007 Nov;51(11):4029-35. Epub 2007 May 25. [Abstract/Free full text]
Share